Press releaseBusiness Wire
Zura Bio
ZURA · NASDAQ
$4.00+$0.19 (+4.99%)TodayMarket closed ·
Prev close $3.81
Latest news
- Press releaseBusiness Wire
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
- NewsVandana Singh
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy
- Press releaseBusiness Wire
Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program
- Press releaseBusiness Wire
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Zura Bio Expands Leadership Team with Appointment of Muzammil Mustufa as Chief Business Officer
- Press releaseBusiness Wire
Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates
- Press releaseBusiness Wire
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- NewsAvi Kapoor
AST SpaceMobile, SBC Medical Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- Press releaseBusiness Wire
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
- Press releaseBusiness Wire
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releaseBusiness Wire
Zura Bio to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- Press releaseBusiness Wire
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseBusiness Wire
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants
- Press releaseBusiness Wire
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors
- Press releaseBusiness Wire
Zura Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit
- NewsAvi Kapoor
Progress Software Posts Upbeat Q4 Earnings, Joins ServisFirst Bancshares, Zura Bio And Other Big Stocks Moving Higher On Wednesday
- Press releaseBusiness Wire
Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer
- Press releaseBusiness Wire
Zura Bio Reports Business Updates and Outlook for 2026
- NewsAvi Kapoor
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- NewsAvi Kapoor
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday
- Press releaseBusiness Wire
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates
- NewsAvi Kapoor
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
- Press releaseBusiness Wire
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
- Press releaseBusiness Wire
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
- Press releaseBusiness Wire
Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releaseBusiness Wire
Zura Bio Announces Chief Financial Officer Transition
- Press releaseBusiness Wire
Zura Bio to Present at the Jefferies Global Healthcare Conference
- Press releaseBusiness Wire
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.